{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:37:06Z","timestamp":1792575426027,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jaccao.2025.02.005","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T12:10:29Z","timestamp":1742213429000},"page":"252-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Immune Checkpoint Inhibitor\u2013Related Myocarditis With or Without Concomitant Myopathy"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9259-4808","authenticated-orcid":false,"given":"Osnat","family":"Itzhaki Ben Zadok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meabh J.","family":"O\u2019Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-1118","authenticated-orcid":false,"given":"Anju","family":"Nohria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10124","key":"10.1016\/j.jaccao.2025.02.005_bib1","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jaccao.2025.02.005_bib2","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.jaccao.2025.02.005_bib3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"7","key":"10.1016\/j.jaccao.2025.02.005_bib4","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor\u2013associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jaccao.2025.02.005_bib5","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.jaccao.2025.02.005_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"41","key":"10.1016\/j.jaccao.2025.02.005_bib7","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.jaccao.2025.02.005_bib8","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"36","key":"10.1016\/j.jaccao.2025.02.005_bib9","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.jaccao.2025.02.005_bib10","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jaccao.2025.02.005_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","article-title":"Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes","volume":"23","author":"Farina","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jaccao.2025.02.005_bib12","article-title":"Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study","volume":"50","author":"Plomp","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"5","key":"10.1016\/j.jaccao.2025.02.005_bib13","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/acn3.51761","article-title":"Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis","volume":"10","author":"Masi","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"10.1016\/j.jaccao.2025.02.005_bib14","first-page":"1947","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series","volume":"271","author":"Vicino","year":"2024","journal-title":"J\u00a0Neurol"},{"issue":"10","key":"10.1016\/j.jaccao.2025.02.005_bib15","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jaccao.2025.02.005_bib16","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/cam4.5050","article-title":"Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: a single-center case series","volume":"12","author":"Longinow","year":"2023","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.jaccao.2025.02.005_bib17","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.jaccao.2025.02.005_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"16","key":"10.1016\/j.jaccao.2025.02.005_bib19","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jaccao.2025.02.005_bib20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","article-title":"Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis","volume":"148","author":"Lehmann","year":"2023","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jaccao.2025.02.005_bib21","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","article-title":"Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis","volume":"29","author":"Fenioux","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jaccao.2025.02.005_bib22","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A\u00a0genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"issue":"7937","key":"10.1016\/j.jaccao.2025.02.005_bib23","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T\u00a0cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jaccao.2025.02.005_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijcme.2014.08.003","article-title":"Cardiac manifestations of myasthenia gravis: a systematic review","volume":"5","author":"Shivamurthy","year":"2014","journal-title":"IJC Metab Endocrine"},{"issue":"10","key":"10.1016\/j.jaccao.2025.02.005_bib25","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s10067-023-06599-4","article-title":"Cardiovascular manifestations in idiopathic inflammatory myopathies","volume":"42","author":"Shah","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.jaccao.2025.02.005_bib26","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.hrthm.2018.11.024","article-title":"Arrhythmias in myocarditis: state of the art","volume":"16","author":"Peretto","year":"2019","journal-title":"Heart Rhythm"},{"issue":"14","key":"10.1016\/j.jaccao.2025.02.005_bib27","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2018.01.070","article-title":"Elevated cardiac troponin T in patients with skeletal myopathies","volume":"71","author":"Schmid","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jaccao.2025.02.005_bib28","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jaccao.2024.07.001","article-title":"Cardiac troponin I and T in ICI myocarditis screening, diagnosis, and prognosis","volume":"6","author":"Barac","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"12 Pt 1","key":"10.1016\/j.jaccao.2025.02.005_bib29","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/clinchem\/41.12.1710","article-title":"Cardiac troponin-I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue","volume":"41","author":"Bodor","year":"1995","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.jaccao.2025.02.005_bib30","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2024.10.080","article-title":"2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis","volume":"85","author":"Drazner","year":"2025","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087325000870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087325000870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T11:32:54Z","timestamp":1746271974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087325000870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2666087325000870"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2025.02.005","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitor\u2013Related Myocarditis With or Without Concomitant Myopathy","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2025.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}